About This Journal

Cancer, an international interdisciplinary journal of the American Cancer Society, publishes high-impact, peer-reviewed original articles and solicited content on the latest clinical research findings. Each issue of Cancer strives to be comprehensive, spanning the breadth of oncology disciplines and providing something for everyone involved in cancer research, risk reduction, treatment, and patient care.

The goal of Cancer is to publish research aligned with the American Cancer Society’s mission to save lives and move us closer to a world without cancer. Cancer is primarily interested in quality papers focused in the following research areas:

  • Risk reduction and early detection
  • Novel approaches to treatment
  • Large randomized clinical trial results
  • Understanding psychosocial aspects of care
  • Moving toward a tobacco-free society
  • Addressing and reducing health disparities

Are you ready to publish your research? Learn why you should consider Cancer as the home for your next paper.

 

Featured Content

Skip slideshow
Annual Report to the Nation

Annual Report to the Nation on the Status of Cancer

Parts 1 and 2 of Annual Report to the Nation on the Status of Cancer are now available. Click below to access the articles.

Part 1: National cancer statistics
Part 2: Early assessment of the COVID-19 pandemic’s impact on cancer diagnosis

Breast Health Equity Along the Cancer Care Continuum: A Collaborative Grant Initiative

Breast Health Equity Along the Cancer Care Continuum: A Collaborative Grant Initiative

A competitive grants program developed by the American Cancer Society and Pfizer Global Medical Grants funded nine community-engaged projects with innovative interventions aimed at reducing breast cancer mortality disparities between Black and White women.

CancerSpeak

Listen to the CancerSpeak podcast

Introducing CancerSpeak, the official podcast of Cancer. Episodes of CancerSpeak are dedicated to the journal’s mission of bringing the best of science to the broadest audiences, offering the latest research, real-life stories, and expert perspectives from the field of oncology.

American Indian and Alaska Native Research Collection

Cancer Turns 75!

Celebrating 75 years of publication, Cancer continues to serve as a beacon for scientific research that is fundamental to achieving cures for cancer. 

Read a special message from Editor-in-Chief Dr. Suresh S. Ramalingam.

American Indian and Alaska Native Research Collection

American Indian and Alaska Native Research Collection

The American Cancer Society is committed to addressing and reducing disparities among AI/AN individuals diagnosed with cancer. Read a special article series featuring the latest research.

A Decade Later: The State of Patient Navigation in Cancer

A Decade Later: The State of Patient Navigation in Cancer

The American Cancer Society is committed to advancing patient navigation efforts that eliminate barriers to quality cancer care, reduce disparities in health outcomes, and foster ongoing health equity. Learn more about the latest efforts in patient navigation in this 2022 research roadmap from Cancer.

Supplement on Multicancer Early Detection

To expedite the development and application of potentially transformative multicancer early detection assays, an international summit was hosted by the Mayo Clinic Cancer Center, the American Cancer Society, and the Union for International Cancer Control on World Cancer Day 2020. Insights shared during this unique summit have been formulated into a series of expert-authored commentaries.

Why Submit to Cancer?

Maximum reach, high impact, no fees. These are just a few of the benefits for authors who submit their research findings to Cancer.

Learn more

COVID-19 and Oncology Special Collection

Access a growing collection of articles addressing the challenges of COVID-19 from the American Cancer Society Journals.

Women in limited-resource settings continue to face significant obstacles to receiving timely, effective, and high-quality breast cancer care. The Breast Healthcare Global Initiative Sixth Global Summit has developed a series of evidence-based phased-implementation pathways to translate resource-stratified guidelines into practice, including a series of prerequisites required for their stepwise implementation and monitoring.

Research on cancer survivorship is more important than ever. Due to rising population growth and improved diagnostics, the number of cancer survivors is increasing. We have curated a special collection of the latest survivorship research from The American Cancer Society Journals. Learn more.

Ovarian Cancer Supplement

Much progress has been made in the treatment of epithelial ovarian cancer over the past three decades. Understanding what those advances are and how to apply those advances requires ongoing diligence. Every other year, the GEICO/ESMO supported International Symposium on Advanced Ovarian Cancer Optimal Therapy Update addresses the advances and puts them into context. This important meeting is memorialized in this series of papers to expand outreach beyond those who attend this outstanding meeting and thus increases the potential to make a difference in the worldwide care of the women for whom we care.

Elise C. Kohn, MD

Section Editor for Cancer, Gynecologic Cancers

Articles

Pediatric cancer incidence among individuals with overgrowth syndromes and overgrowth features: A population‐based assessment in seven million children

Gillean K. Connolly MD, MPH, Rachel D. Harris BA, Charles Shumate DrPH, Surya P. Rednam MD, Mark A. Canfield PhD, Sharon E. Plon MD, PhD, Joanne Nguyen MD, Jeremy M. Schraw PhD, Philip J. Lupo PhD, 
  •  3 October 2023

Abstract

Children with either overgrowth syndromes or features are at a significantly increased risk for childhood cancer. Results from this study may ultimately be used to guide recommendations for cancer surveillance in children with overgrowth syndromes/features and may also inform future research into cancer etiology.

Open access

What are the most effective exercise, physical activity and dietary interventions to improve body composition in women diagnosed with or at high‐risk of breast cancer? A systematic review and network meta‐analysis

Christine Kudiarasu MSc, Pedro Lopez PhD, Daniel A. Galvão PhD, Robert U. Newton PhD, Dennis R. Taaffe PhD, Lorna Mansell BSc, Brianna Fleay BEd, Christobel Saunders MBBS, Caitlin Fox-Harding PhD, Favil Singh PhD, 
  •  3 October 2023

Abstract

Exercise, nutrition, and weight management guidelines are widely recognized; however, no recommendations have specifically focused on improving body composition in breast cancer patients. This review highlights the most effective interventions to improve body composition and assist in weight management for breast cancer patients during or following treatment.

Open access

Effect of preoperative programmed death‐1 or programmed death ligand‐1 immune check point inhibition on complications after surgery for primary head and neck cancer

Ramez Philips MD, Angela Alnemri MD, Dev Amin MD, Jena Patel MD, Michael C. Topf MD, Jennifer M. Johnson MD, PhD, Voichita BarAd MD, Rita Axelrod MD, Athanassios Argiris MD, Christopher Fundakowski MD, Adam J. Luginbuhl MD, David M. Cognetti MD, Joseph M. Curry MD, 
  •  3 October 2023

Abstract

In this study, nICI did not increase the risk of overall complications after adjusting for important confounders. Definitive surgery can be conducted safely after nICI.

More articles
free access

Index for rating diagnostic tests

W. J. Youden Ph.D., 
  •  32-35
  •  1950
First page image
free access

The ever‐increasing importance of cancer as a leading cause of premature death worldwide

Freddie Bray PhD, Mathieu Laversanne MSc, Elisabete Weiderpass MD, Isabelle Soerjomataram MD, 
  •  3029-3030
  •  4 June 2021

Abstract

Cardiovascular disease and cancer are now the leading causes of premature death in the majority of countries worldwide, and cancer is likely to surpass cardiovascular disease as the leading causes of death at ages 30-70 in most countries over the course of this century. Governments must factor in these transitions in formulating and implementing their cancer and noncommunicable disease plans and tailor cost-effective measures to the local disease profile.

free access

Osteosarcoma incidence and survival rates from 1973 to 2004

Lisa Mirabello PhD, Rebecca J. Troisi ScD, Sharon A. Savage MD, 
  •  1531-1543
  •  5 February 2009

Abstract

This comprehensive, population-based description of osteosarcoma identified important differences in incidence, survival, pathologic subtype, and anatomic site among age groups and quantified the impact of osteosarcoma in Paget disease or as a second cancer on incidence and mortality rates. These findings may have implications for understanding the biology and epidemiology of osteosarcoma.

Open access

Annual report to the nation on the status of cancer, part 1: National cancer statistics

Kathleen A. Cronin PhD, MPH, Susan Scott MPH, Albert U. Firth BS, Hyuna Sung PhD, S. Jane Henley MSPH, Recinda L. Sherman MPH, PhD, CTR, Rebecca L. Siegel MPH, Robert N. Anderson PhD, Betsy A. Kohler MPH, Vicki B. Benard PhD, Serban Negoita MD, DrPH, Charles Wiggins PhD, William G. Cance MD, Ahmedin Jemal DVM, PhD, 
  • Cancer
  •  4251-4284
  •  27 October 2022

Abstract

The American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries collaborate annually to provide updated information about cancer occurrence and trends in the United States. Part 1 of this year's report provides information on cancer incidence and mortality rates and trends for males and females and by race/ethnicity for common cancer sites, with an in-depth look at pancreatic cancer.

Open access

Risk of prostate cancer and death after benign transurethral resection of the prostate—A 20‐year population‐based analysis

Maria Hilscher MD, Andreas Røder MD, PhD, J. Thomas Helgstrand PhD, MD, Nina Klemann PhD, MD, Klaus Brasso PhD, MD, Andrew Julian Vickers PhD, Hein Vincent Stroomberg PhD, MSc, 
  • Cancer
  •  3674-3680
  •  17 August 2022

Abstract

Men with low prostate-specific antigen (PSA) levels and a benign transurethral resection of the prostate can be reassured about their cancer risk and do not need to be monitored differently than any other men, but patients with high PSA levels should be considered for further follow-up. This study's findings add to a body of literature suggesting that normal histology from the prostate entails a low risk of death from the disease.

Open access

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy

Sharon Elad DMD, MSc, Karis Kin Fong Cheng RN, PhD, Rajesh V. Lalla DDS, PhD, Noam Yarom DMD, Catherine Hong BDS, MS, Richard M. Logan BDS, MDS, PhD, Joanne Bowen PhD, Rachel Gibson PhD, Deborah P. Saunders DDS, Yehuda Zadik DMD, MHA, Anura Ariyawardana BDS, MS, Maria Elvira Correa DDS, PhD, Vinisha Ranna DDS, Paolo Bossi MD, for the Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO), 
  • Cancer
  •  4423-4431
  •  28 July 2020

Abstract

The Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology developed clinical practice guidelines for the management of mucositis, with the first edition published in 2004 and periodically updated. This summary presents the 2019/2020 guidelines update, which is based on a systematic review, and generates a tool that will help clinicians to select evidence-based interventions.

Open access

The BiTE (bispecific T‐cell engager) platform: Development and future potential of a targeted immuno‐oncology therapy across tumor types

Hermann Einsele MD, Hossein Borghaei DO, Robert Z. Orlowski MD, Marion Subklewe MD, Gail J. Roboz MD, Gerhard Zugmaier MD, Peter Kufer MD, Karim Iskander MD, Hagop M. Kantarjian MD, 
  • Cancer
  •  3192-3201
  •  13 May 2020

Abstract

This review provides an overview of immuno-oncology therapies and those in development. It specifically focuses on bispecific T-cell engager (BiTE) technology, its mechanism of action, types of cancer in which it has had success, half-life-extended BiTE molecules, and their potential as an off-the-shelf, targeted immunotherapy.

free access

The ever‐increasing importance of cancer as a leading cause of premature death worldwide

Freddie Bray PhD, Mathieu Laversanne MSc, Elisabete Weiderpass MD, Isabelle Soerjomataram MD, 
  • Cancer
  •  3029-3030
  •  4 June 2021

Abstract

Cardiovascular disease and cancer are now the leading causes of premature death in the majority of countries worldwide, and cancer is likely to surpass cardiovascular disease as the leading causes of death at ages 30-70 in most countries over the course of this century. Governments must factor in these transitions in formulating and implementing their cancer and noncommunicable disease plans and tailor cost-effective measures to the local disease profile.

Recent issues

Latest news

More news >